Literature DB >> 24587679

Longitudinal analysis of inflammation and microbiota dynamics in a model of mild chronic dextran sulfate sodium-induced colitis in mice.

Luigia De Fazio1, Elena Cavazza1, Enzo Spisni1, Antonio Strillacci1, Manuela Centanni1, Marco Candela1, Chiara Praticò1, Massimo Campieri1, Chiara Ricci1, Maria Chiara Valerii1.   

Abstract

AIM: To characterize longitudinally the inflammation and the gut microbiota dynamics in a mouse model of dextran sulfate sodium (DSS)-induced colitis.
METHODS: In animal models, the most common method used to trigger colitis is based on the oral administration of the sulfated polysaccharides DSS. The murine DSS colitis model has been widely adopted to induce severe acute, chronic or semi-chronic colitis, and has been validated as an important model for the translation of mice data to human inflammatory bowel disease (IBD). However, it is now clear that models characterized by mild intestinal damage are more accurate for studying the effects of therapeutic agents. For this reason, we have developed a murine model of mild colitis to study longitudinally the inflammation and microbiota dynamics during the intestinal repair processes, and to obtain data suitable to support the recovery of gut microbiota-host homeostasis.
RESULTS: All plasma cytokines evaluated, except IL-17, began to increase (P < 0.05), after 7 d of DSS administration. IL-17 only began to increase 4 d after DSS withdrawal. IL-1β and IL-17 continue to increase during the recovery phase, even when clinical signs of colitis had disappeared. IL-6, IL-10 and IFN-γ reached their maxima 4 d after DSS withdrawal and decreased during the late recovery phase. TNFα reached a peak (a three- fold increase, P < 0.05), after which it slightly decreased, only to increase again close to the end of the recovery phase. DSS administration induced profound and rapid changes in the mice gut microbiota. After 3 d of DSS administration, we observed a major reduction in Bacteroidetes/Prevotella and a corresponding increase in Bacillaceae, with respect to control mice. In particular, Bacteroidetes/Prevotella decreased from a relative abundance of 59.42%-33.05%, while Bacillaceae showed a concomitant increase from 2.77% to 10.52%. Gut microbiota rapidly shifted toward a healthy profile during the recovery phase and returned normal 4 d after DSS withdrawal. Cyclooxygenase 2 expression started to increase 4 d after DSS withdrawal (P < 0.05), when dysbiosis had recovered, and continued to increase during the recovery phase. Taken together, these data indicated that a chronic phase of intestinal inflammation, characterized by the absence of dysbiosis, could be obtained in mice using a single DSS cycle.
CONCLUSION: Dysbiosis contributes to the local and systemic inflammation that occurs in the DSS model of colitis; however, chronic bowel inflammation is maintained even after recovery from dysbiosis.

Entities:  

Keywords:  Colitis, Dysbiosis; Cyclooxygenase 2; Dextran sulfate sodium; Inflammation

Mesh:

Substances:

Year:  2014        PMID: 24587679      PMCID: PMC3934475          DOI: 10.3748/wjg.v20.i8.2051

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  35 in total

Review 1.  The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models.

Authors:  Sandra Nell; Sebastian Suerbaum; Christine Josenhans
Journal:  Nat Rev Microbiol       Date:  2010-07-12       Impact factor: 60.633

2.  Microbial fingerprinting detects unique bacterial communities in the faecal microbiota of rats with experimentally-induced colitis.

Authors:  Ashis K Samanta; Valeria A Torok; Nigel J Percy; Suzanne M Abimosleh; Gordon S Howarth
Journal:  J Microbiol       Date:  2012-04-27       Impact factor: 3.422

Review 3.  Interactions between the intestinal microbiota and innate lymphoid cells.

Authors:  Vincent L Chen; Dennis L Kasper
Journal:  Gut Microbes       Date:  2013-12-16

4.  Microbial ecology of the murine gut associated with the development of dextran sodium sulfate-induced colitis.

Authors:  Nabeetha A Nagalingam; John Y Kao; Vincent B Young
Journal:  Inflamm Bowel Dis       Date:  2010-11-08       Impact factor: 5.325

5.  Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL-17A expression and inflammation in the intestinal mucosa.

Authors:  Doo-Jin Kim; Kwang-Soon Kim; Mi-Young Song; Sang-Hwan Seo; Su-Jin Kim; Bo-Gie Yang; Myoung-Ho Jang; Young-Chul Sung
Journal:  Clin Immunol       Date:  2012-07-13       Impact factor: 3.969

6.  Unbalance of intestinal microbiota in atopic children.

Authors:  Marco Candela; Simone Rampelli; Silvia Turroni; Marco Severgnini; Clarissa Consolandi; Gianluca De Bellis; Riccardo Masetti; Giampaolo Ricci; Andrea Pession; Patrizia Brigidi
Journal:  BMC Microbiol       Date:  2012-06-06       Impact factor: 3.605

7.  Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon.

Authors:  Hamed Laroui; Sarah A Ingersoll; Hong Chun Liu; Mark T Baker; Saravanan Ayyadurai; Moiz A Charania; Famina Laroui; Yutao Yan; Shanthi V Sitaraman; Didier Merlin
Journal:  PLoS One       Date:  2012-03-09       Impact factor: 3.240

8.  Prevention of chronic experimental colitis induced by dextran sulphate sodium (DSS) in mice treated with FR91.

Authors:  Valter R M Lombardi; Ignacio Etcheverría; Iván Carrera; Ramón Cacabelos; Antonio R Chacón
Journal:  J Biomed Biotechnol       Date:  2012-02-12

9.  L-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitis.

Authors:  Lori A Coburn; Xue Gong; Kshipra Singh; Mohammad Asim; Brooks P Scull; Margaret M Allaman; Christopher S Williams; Michael J Rosen; M Kay Washington; Daniel P Barry; M Blanca Piazuelo; Robert A Casero; Rupesh Chaturvedi; Zhongming Zhao; Keith T Wilson
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

Review 10.  Dextran sodium sulphate colitis mouse model: traps and tricks.

Authors:  Martina Perše; Anton Cerar
Journal:  J Biomed Biotechnol       Date:  2012-05-14
View more
  31 in total

1.  Cyclooxygenase-2 silencing for the treatment of colitis: a combined in vivo strategy based on RNA interference and engineered Escherichia coli.

Authors:  Enzo Spisni; Maria C Valerii; Luigia De Fazio; Elena Cavazza; Francesca Borsetti; Annamaria Sgromo; Marco Candela; Manuela Centanni; Fernando Rizello; Antonio Strillacci
Journal:  Mol Ther       Date:  2014-11-13       Impact factor: 11.454

2.  Prescription Opioids induce Gut Dysbiosis and Exacerbate Colitis in a Murine Model of Inflammatory Bowel Disease.

Authors:  Umakant Sharma; Rohini Khatri Olson; Federico Nicolas Erhart; Li Zhang; Jingjing Meng; Bradley Segura; Santanu Banerjee; Madhulika Sharma; Ashok Kumar Saluja; Sundaram Ramakrishnan; Maria T Abreu; Sabita Roy
Journal:  J Crohns Colitis       Date:  2020-07-09       Impact factor: 9.071

3.  Mesenteric injection of adipose-derived mesenchymal stem cells relieves experimentally-induced colitis in rats by regulating Th17/Treg cell balance.

Authors:  Zheng-Wei Fu; Zhen-Yu Zhang; Hai-Yan Ge
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

4.  Neutralization of IL-1α ameliorates Crohn's disease-like ileitis by functional alterations of the gut microbiome.

Authors:  Paola Menghini; Daniele Corridoni; Ludovica F Buttó; Abdullah Osme; Sushma Shivaswamy; Minh Lam; Giorgos Bamias; Theresa T Pizarro; Alexander Rodriguez-Palacios; Charles A Dinarello; Fabio Cominelli
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

5.  A murine model of pediatric inflammatory bowel disease causes microbiota-gut-brain axis deficits in adulthood.

Authors:  Eloisa Salvo; Patricia Stokes; Ciara E Keogh; Ingrid Brust-Mascher; Carly Hennessey; Trina A Knotts; Jessica A Sladek; Kavi M Rude; Michelle Swedek; Gonzalo Rabasa; Mélanie G Gareau
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-07-29       Impact factor: 4.052

6.  Effect of Early-life Gut Mucosal Compromise on Disease Progression in NOD Mice.

Authors:  Katja M Bendtsen; Camilla Hf Hansen; Lukasz Krych; Karsten Buschard; Helene Farlov; Axel K Hansen
Journal:  Comp Med       Date:  2017-10-01       Impact factor: 0.982

7.  Attenuation of Colitis by Lactobacillus casei BL23 Is Dependent on the Dairy Delivery Matrix.

Authors:  Bokyung Lee; Xiaochen Yin; Stephen M Griffey; Maria L Marco
Journal:  Appl Environ Microbiol       Date:  2015-07-10       Impact factor: 4.792

8.  Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice.

Authors:  Lien Van den Bossche; Pieter Hindryckx; Lindsey Devisscher; Sarah Devriese; Sophie Van Welden; Tom Holvoet; Ramiro Vilchez-Vargas; Marius Vital; Dietmar H Pieper; Julie Vanden Bussche; Lynn Vanhaecke; Tom Van de Wiele; Martine De Vos; Debby Laukens
Journal:  Appl Environ Microbiol       Date:  2017-03-17       Impact factor: 4.792

9.  Therapeutic Potential of Secreted Molecules Derived from Human Amniotic Fluid Mesenchymal Stem/Stroma Cells in a Mice Model of Colitis.

Authors:  E Legaki; M G Roubelakis; G E Theodoropoulos; A Lazaris; A Kollia; G Karamanolis; E Marinos; M Gazouli
Journal:  Stem Cell Rev Rep       Date:  2016-10       Impact factor: 5.739

10.  ESRRA (estrogen related receptor alpha) is a critical regulator of intestinal homeostasis through activation of autophagic flux via gut microbiota.

Authors:  Sup Kim; June-Young Lee; Seul Gi Shin; Jin Kyung Kim; Prashanta Silwal; Young Jae Kim; Na-Ri Shin; Pil Soo Kim; Minho Won; Sang-Hee Lee; Soo Yeon Kim; Miwa Sasai; Masahiro Yamamoto; Jin-Man Kim; Jin-Woo Bae; Eun-Kyeong Jo
Journal:  Autophagy       Date:  2020-12-15       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.